Connaught Biosciences (CNTB, Financial) experienced a significant drop in stock price, declining by 5.11%. The current price stands at $1.39 per share with a trading volume of 36,535 shares and a turnover rate of 0.07%. The stock's amplitude is 8.87%.
Recent financial results revealed revenue of $24.12 million and a net profit of $7.65 million, resulting in an earnings per share of $0.14. The gross profit amounted to $23.64 million, while the price-to-earnings ratio stands at -3.62.
Institutional ratings show that 100% of analysts covering the stock recommend buying, with no hold or sell recommendations present.
Within the biotechnology sector, where Connaught Biosciences operates, the overall decline was 0.24%. Notably, companies such as Lexaria Bioscience Corp, Entero Therapeutics Inc., and Cardio Diagnostics Holdings Inc. saw significant gains. Meanwhile, Aditxt, Inc., Seelos Therapeutics, Inc., and Theriva Biologics, Inc. were notably active, with turnover rates of 17427.92%, 92.49%, and 77.30% respectively. Aditxt, Inc., Geovax Labs Inc, and Revolution Medicines Inc showed high amplitude, with figures of 69.59%, 58.64%, and 56.57% respectively.
Connaught Biosciences is a clinical-stage company focusing on developing next-generation immunomodulators for severe autoimmune diseases and inflammation, leveraging expertise in T cell regulatory biology. The company's pipeline includes drug candidates like CBP-201, CBP-307, and CBP-174.
